Compare Toyota Motor Corp (TM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toyota Motor Corp vs TransMedics Group Inc — how do they compare? Toyota Motor Corp trades at $185.7 (market cap $217.38B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Toyota Motor Corp is far larger — about 79.3× TransMedics Group Inc's market cap, and Toyota Motor Corp pays a 3.37% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toyota Motor Corp for 116 Days and TransMedics Group Inc for 24 Days on average.
| TM | TMDX | |
|---|---|---|
Market Cap | $217.38B | $2.74B |
Volume | 291,250 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $248.29 | $150.42 |
52-Week Low | $166.50 | $61.99 |
Typical Hold Time | 116 Days | 24 Days |
Enterprise Value | $410.96B | $3.13B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Toyota Motor trades at $182.91, down 1.43% with bearish technical signals despite strong fundamentals. The stock shows attractive valuation metrics with P/E of 8.38 and P/B of 0.93, while consistently beating earnings expectations in recent quarters. Recent news highlights Toyota's growing U.S. market share and electrification progress with 37.8% growth in EV sales. Cash flow trends show improvement with projected 2026 operating cash flow of $4.13T.
Toyota presents a value opportunity with solid profitability and market positioning, though near-term technical weakness and China sales challenges warrant caution. The company's hybrid technology leadership and North American expansion provide growth catalysts, while analyst consensus leans neutral with 62.5% hold ratings. Debt levels remain manageable at 41.29% debt-to-asset ratio.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
